Floatz logo

mk-6240

Demyelinating Disease

Yale UniversityUNKNOWNPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Demyelinating Disease cohort.

Asset / SponsorPhaseRating
Interferon ?1 (Human Fibroblast Protein Moiety)
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Phase 4BB
Methotrexate
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Phase 4BB
Pittsburgh Compound B Unlabelled
Yale University
Phase 2B
ER-176
Mayo Clinic
Phase 2CCC
[ 18f]3f4ap
Yale University
Phase 1CC

Same molecule, other indications

mk-6240 is also rated in:

Alzheimer diseaseActive
BB
Indicative · Phase 3
65 / 100
View asset →
Down syndromeActive
B
Indicative · Phase 3
60 / 100
View asset →
cognitive disorderActive
B
Indicative · Phase 3
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →